Fundamentals · MRK

Valuation Summary for MRK

AI-generated plain-English read of valuation summary for MRK. Updated daily.

Fair multiples, stable

moderate

Multiples (14.3x) sit in fair territory: the market is pricing in roughly what the business can deliver. No valuation edge or urgency; other signals drive the thesis here.

What will probably happen

  • Multiples are stable: no near-term catalyst for a valuation re-rating from the multiple direction alone.
  • Income profile supports a 'wait and collect' posture: FCF yield or dividends cover the cost of waiting for the thesis to play out.

What to do

If you HOLD this stock
Reasonably priced with stable multiples: a hold-the-line setup. No urgent action from the valuation dimension.
If you're EVALUATING this stock
Acceptable entry: fair multiples don't demand a discount premium. Expect returns roughly in line with sector beta.
If you trade OPTIONS
No valuation edge from multiples alone. Trade other signals (momentum, earnings) rather than valuation-driven structures.

8 quarters / 3 populated multiples: directionally informative; use more data for full conviction.

Technical details

Technical analysis

P/Book
5.0x
P/Sales
4.0x
EV/EBITDA
--
FCF yield
--
EV/Revenue
--
P/E (forward)
--
Dividend yield
3.1%
Earnings yield
--
Income profile
Income Friendly
P/E (trailing)
14.3x
Sector context
Pharmaceuticals
Sector comparison
Unknown Vs Sector
Absolute valuation
Fairly Valued
History (quarters)
8
Multiple trajectory
Stable

Key levels

Key price and metric levels
LevelValue
pb ratio4.978
pe ratio14.347
ps ratio4.028
n quarters8
current price147.76
prior year pe14.732
dividend yield0.031

Caveats

  • Multiples should be read alongside growth and quality metrics: a low P/E on declining earnings isn't cheap, it's a value trap warning.
  • Sector context wasn't provided; absolute multiples may mislead without industry comparison.

More Fundamentals reads for MRK

For informational and educational purposes only. Not financial advice. Learn more